Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by M101on Feb 19, 2022 10:00pm
174 Views
Post# 34445694

RE:RE:class war

RE:RE:class war

azzymaa wrote: why doesn't pmn just get bought out by a bigger company if pmn310 is so valuable?


It's a great question with many possible answers.
Consider Moderna, the mrna vaccine tech wasn't that valuable until it was.
Consider Biogen, they had an in-house strategy and careers depended upon it.
Consider Gene and Elliot, they planned for a quick-out but didn't have the connections or street cred to pull it off.
Consider the history of public microcap pharmas, there aren't many cause they run out of money long before getting to P3
Consider big pharma, it works with the biggest investment banks to direct almost all institutional money away from potential competition, and it mostly owns the regulators who can ensure reaching P3 is prohibitively expensive, or make the path faster and cheaper.

Money talks but people make decisions.




 

<< Previous
Bullboard Posts
Next >>